

N=1485

Arm 1 vs. Arm 2

Arm 1	Carboplatin AUC 5	q3w
	Paclitaxel 175mg/m^2	q3w
Arm 2	Carboplatin AUC 5	q3w
	Paclitaxel 80mg/m^2	q1w
Arm 3	Carboplatin AUC 2	q1w
	Paclitaxel 80mg/m^2	q1w

Arm 1 vs. Arm 3



@24Sept2013: n=778 (UK=742, KGOG=18, GICOM= 10, ICORG=6)

ICON8 trials programme, revised design

ICON8A

N=1485

Diagnosis of Stage IC-IV EOC/PPC/FTC

Randomise 1:1:1

- Arm A1 — 6 cycles
- Arm A2 — 6 cycles
- Arm A3 — 6 cycles

Arm A1	Carboplatin AUC 5	q3w
	Paclitaxel 175mg/m^2	q3w
Arm A2	Carboplatin AUC 5	q3w
	Paclitaxel 80mg/m^2	q1w
Arm A3	Carboplatin AUC 2	q1w
	Paclitaxel 80mg/m^2	q1w

NB. Patients with Stage III & residual disease after surgery or who are planned to receive neoadjuvant chemothererapy OR any patients with stage IV disease are still eligible for ICON8A as well as B so that they may still enter the trial if:

- they have contra-indications to or decline bevacizumab
- their site does not have access to bev, e.g. in Australia

ICON8B

N=1170

Diagnosis of Stage III-IV EOC/PPC/FTC with residual disease after surgery or planned for neoadjuvant chemotherapy

Randomise 1:1:1

- Arm B1 — 6 cycles
- Arm B2 — 6 cycles
- Arm B3 — 6 cycles

16 cycles maintenance Bevacizumab

Arm B1	Carboplatin AUC 5	q3w
	Paclitaxel 175mg/m^2	q3w
	Bevacizumab 15mg/kg	q3w
Arm B2	Carboplatin AUC 5	q3w
	Paclitaxel 80mg/m^2	q1w
Arm B3	Carboplatin AUC 5	q3w
	Paclitaxel 80mg/m^2	q1w
	Bevacizumab 15mg/kg	q3w